Roche’s hopes of getting its chronic obstructive pulmonary disease (COPD) drug astegolimab to regulators this year have taken ...

With its Poolbeg Pharma merger plans having bitten the dust and key assets sold off to Gilead, Hookipa Pharma has decided ...

On an investor call Friday, analysts grilled the company over its apparent lack of transparency on the matter.

Kennedy Jr. has downplayed the effectiveness of the long-used vaccine and instead promoted the development of new treatments ...

Sail Biomedicines is shrinking its crew for the second time this year. | Sail Biomedicines is shrinking its crew for the ...

To secure the antibody, I-Mab is paying $1.8 million upfront to buy Bridge Health, to be followed by noncontingent quarterly ...

Heartflow is once again looking for a path to go public, with a filing for a Nasdaq IPO. | The former Fierce Medtech Fierce ...

The PD-1xVEGF dealmaking wave that has captivated Western pharma companies is now surging within China. | Sino Biopharm said ...

Reeling from the deaths of two patients who took Duchenne muscular dystrophy gene therapy Elevidys, Sarepta is launching a ...

The U.K. is establishing a new biosecurity center designed to improve research into potentially pandemic-causing pathogens ...

With GSK kicking its research and development engine into high gear in recent years, a shuffling of the scientific priorities ...

After 45 years at Henry Schein, including more than three decades as its CEO, Stanley Bergman has announced plans to retire ...